Fagron The Fagron Trifecta: North America, EMEA and LATAM
Fagron focuses on the optimisation and innovation of pharmaceutical compounding with the aim of widening the therapeutic scope for the prescriber to facilitate personalized medicine solutions for the patient. Within the scope of this note, we review the current status of Fagron through a geographic segmentation of the company. While recent results revealed some concerns in the NA region, we believe that this will be the main growth driver for the company. Upon reviewing our Fagron model, we have increased our WACC to 8.9% and consequently lower our PT to € 18.5 while maintaining our BUY rating.Fagron supplies products, services to professionals and institutions in the healthcare sector in Europe, the U.S.A. and Brazil. Co.'s activities are subdivided into four divisions. Through Fagron, Co. offers products and concepts for pharmaceutical compounding. Through Arseus Dental, Co. supplies dental products and concepts to dentists and dental laboratories in Belgium, the Netherlands, France, Germany and Switzerland. Through Arseus Medical, Co. supplies medical and surgical products to specialists, elderly homes, homecare nurses and hospitals in Belgium and the Netherlands. Through Corilus, Co. supplies ICT total solutions for medical specialists in Belgium, the Netherlands and France.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.